Allergan plc (AGN) chief commercial officer Bill Meury highlighted medical aesthetics as he discussed some of the Dublin drugmaker's catalysts at Leerink Partners LLC's annual global healthcare conference.
The company's medical aesthetics business is strong both domestically and internationally, Meury said on Thursday, Feb. 15, in New York.
The medical aesthetics unit, which includes Botox, had revenue of $2.45 billion in the U.S. in 2017, compared with $1.62 billion in 2016. International revenue was $1.37 billion, compared with $1.06 billion in 2016.
"Despite all the activity from smaller companies that are developing other products, I think the long-term outlook for that business is exceptional," Meury said.
"We've just scratched the surface of medical aesthetics," he added. "The future is about market expansion, not any market share battle [with other firms]."
Revance in December unveiled positive top-line results from two Phase 3 studies evaluating RT002 for the treatment of glabellar, or frown, lines. In the announcement, Newark, Calif.-based Revance said it believed that RT002, if approved by the U.S. Food and Drug Administration, would be the first neuromodulator to work for as long as six months.
As for Evolus, the FDA gave a Prescription Drug User Fee Act (PDUFA) date of May 15 for the company's DWP-450 for the treatment of glabellar lines. The PDUFA date is when the FDA plans to have completed its review of an application.
Botox competes with Galderma SA's Dysport and Merz Pharma GmbH & Co. KGaA's Xeomin. Galderma is a unit of Nestlé SA.
Among the other topics Meury discussed at the Leerink conference was Vraylar (cariprazine). Allergan and Gedeon Richter plc in December reported positive topline results from a Phase 3 study of cariprazine for adults with major depressive episodes associated with bipolar I disorder. Allergan plans to submit a supplemental new drug application to the FDA in the second half of the year.